Agonistic antibodies that bind CD40

• US 10,633,444 B2
• Filed: 04/05/2019
• Issued: 04/28/2020
• Est. Priority Date: 04/18/2016
• Status: Active Grant

• Current Assignee: Celldex Therapeutics Incorporated
• Original Assignee: Celldex Therapeutics Incorporated
• Inventors: Keler, Tibor, Goldstein, Joel, Vitale, Laura A., He, Lizhen, O'Neill, Tom, Crocker, Andrea, Sundarapandiyan, Karuna, Thomas, Lawrence J., Widger, Jenifer
• Primary Examiner(s): Gambel, Phillip
• Application Number:
  US16/376,585
• Publication Number:
  US 20190322743A1
• Time in Patent Office: 389 Days
• Field of Search: None
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/385 Haptens or antigens, bound to carriers
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 14/54 Interleukins [IL]
• CPC Class Codes: C07K 14/70575 NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 NGF C07K14/48, TNF C07K14/525
• CPC Class Codes: C07K 14/715 for cytokines; for lymphokines; for interferons
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/74 Inducing cell proliferation
• CPC Class Codes: C07K 2317/75 Agonist effect on antigen
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

Claims

1. An isolated antibody which binds to human CD40 and comprises heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs:

19, 21, 23, respectively, and/or light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs;

25, 27, 29, respectively.

2. The antibody of claim 1, wherein the antibody comprises heavy and light chain variable regions having the amino acid sequence set forth in SEQ ID NOs:

17 and 18, respectively.

3. The antibody of claim 2, wherein the antibody comprises heavy and light chains having the amino acid sequence set forth in SEQ ID NOs:

135 and 136, respectively.

4. The antibody of claim 1 wherein the antibody is a human antibody.

5. The antibody of claim 1, wherein the antibody comprises a human IgG2 constant region.

6. The antibody of claim 1, wherein the antibody is an antigen binding fragment, a Fab, Fab′

, (Fab′

)2, Fv, or scFv fragment.

7. A composition comprising the antibody of claim 1 and a carrier.

8. The composition of claim 7, further comprising an adjuvant.